Latest Heptares Therapeutics Ltd Stories
LONDON and BOSTON, September 16, 2014 /PRNewswire/ -- Heptares Therapeutics notes that its Chief Scientific Officer, Fiona Marshall, will give a presentation entitled "Structure-based
LONDON and BOSTON, May 29, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Malcolm Weir,
WELWYN GARDEN CITY, England, May 9, 2011 /PRNewswire/ -- - Best-in-Class Candidate With Potential in Treatment of CNS Diseases Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.
CAMBRIDGE, England, April 11, 2011 /PRNewswire/ -- - Deal Includes GBP4.5 Million Upfront Cash and Equity, Up to GBP60.5 Million in Future Milestone Payments, and Royalties on Product Sales Heptares Therapeutics and Takeda Pharmaceutical Company today announced the formation of a two-year drug discovery collaboration focused on a single G-protein coupled receptor (GPCR) that plays an important role in the pathology of central nervous system disorders.